‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales
Regeneron and Sanofi have opportunity to appeal or to reach resolution with Amgen after district judge delays imposition of permanent injunction for 30 days in PCSK9 patent case.
You may also be interested in...
Claiming Pfizer’s Abrysvo infringes four of its patents, GSK asks court to permanently enjoin Pfizer from making or selling the vaccine in the US but would exempt the pending maternal indication.
In unanimous decision, court finds Amgen patent offered persons skilled in the art “little more than advice to engage in ‘trial and error.’” Lawyers say the ruling prevents function claims from monopolizing a therapeutic target and retains status quo on enablement requirement.
Big biologic makers line up on opposite sides of dispute between Amgen and Sanofi over whether Amgen’s Repatha patents cover analogous antibodies with the same functional characteristics.